A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and efficacy of two dose levels of pimavanserin (ACP-103)
compared to placebo in patients with Parkinson's disease psychosis.